Literature DB >> 28404085

POLE mutations in colorectal cancer: a new biomarker?

Cathy Eng1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28404085     DOI： 10.1016/S2468-1253(16)30030-9

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


× No keyword cloud information.
  3 in total

Review 1.  The Developing Story of Predictive Biomarkers in Colorectal Cancer.

Authors:  Stergios Boussios; Mehmet Akif Ozturk; Michele Moschetta; Afroditi Karathanasi; Nikolaos Zakynthinakis-Kyriakou; Konstantinos H Katsanos; Dimitrios K Christodoulou; Nicholas Pavlidis
Journal:  J Pers Med       Date:  2019-02-07

Review 2.  Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.

Authors:  Pauline du Rusquec; Ombline de Calbiac; Marie Robert; Mario Campone; Jean Sebastien Frenel
Journal:  Cancer Manag Res       Date:  2019-05-15       Impact factor: 3.989

3.  Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.

Authors:  Hanguang Hu; Wen Cai; Dehao Wu; Wangxiong Hu; Li Dong Wang; Jianshan Mao; Shu Zheng; Weiting Ge
Journal:  Cancer Med       Date:  2020-10-30       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.